Peptide-based uPAR inhibitors such as UPARANT, mimicking uPAR’s chemotactic sequence and antagonizing uPAR–integrin/GPCR interaction, effectively suppress angiogenesis in vivo and in vitro tumor models [126]. Here, PLAUR is linked to neoplasm.